MircroPort Medbot-B

Shanghai MicroPort MedBot surged in the morning session, closing 4.72% higher at HK$21.08, driven by its first-ever semi-annual profit forecast. The company expects H1 2026 net profit between RMB 28 million and RMB 40 million, reversing a year-ago loss, with revenue jumping over 134% YoY to HK$205 million. Citi raised its target price to HK$38 with a Buy rating. However, the stock remains below its 20-day MA (HK$22.62) and 60-day MA (HK$24.32), down 13.75% YTD, and still 40% off its 52-week high of HK$35.34.

Shanghai MicroPort MedBot fell 4.2% to close at HKD 19.99, after opening at HKD 21.0 and declining to an intraday low of HKD 19.75 in the afternoon session. The company reported its first-ever semi-annual profit forecast, expecting a net profit of RMB 28-40 million for H1 2026, driven by over 200 global installations of its Toumai surgical robot and surging exports. Revenue grew over 130% YoY for two consecutive quarters, reaching HKD 209 million in Q4, while net loss narrowed 61%. However, despite a Citi Buy rating, no specific target price was disclosed, and the stock remains 43% below its 52-week high of HKD 35.34, below both the 20-day (HKD 22.92) and 60-day (HKD 24.50) moving averages, with a YTD decline of 18%.

Shanghai MicroPort MedBot tumbled 5.03% to close at HKD 20.40, erasing gains from its interim profit turnaround forecast. The stock hit an intraday high of HKD 21.98 before sliding steadily to a low of HKD 20.40, with 3.39 million shares traded and a turnover rate of 0.33%. The company guided H1 net profit of RMB 28-40 million, a reversal from a year-earlier loss, and revenue surged over 134% YoY; however, the stock remains 42.28% below its 52-week high of HKD 35.34 and well below the 20-day moving average of HKD 23.18, prompting profit-taking. Citi maintained a Buy rating post-announcement, citing revenue beat; Toumai robot global installations exceeded 200 units and secured EU CE mark, underpinning export growth.

MicroPort MedBot surged 5.04% to close at HK$21.24 in the morning session, driven by its first-ever semi-annual profit forecast of HK$28-40 million, reversing prior losses. Citi subsequently rated it Buy/High Risk, citing revenue growth that surpassed expectations, supported by Toumai surgical robot global installations exceeding 200 units and booming exports. However, the stock trades 39.9% below its 52-week high of HK$35.34 and is down 13.09% year-to-date, significantly underperforming the 20-day and 60-day moving averages of HK$23.32 and HK$25.04, respectively, with a PB of 48.18x.

2252.HK surged in the morning session before retreating, hitting a high of 21.22 HKD early and then falling steadily to close the morning at 20.02 HKD, down 5.03%, with a turnover of approximately 101 million HKD, driven by news. The company expects a turnaround in interim results to a net profit of 28 million to 40 million HKD, reversing prior losses, supported by strong product progress including Toumai surgical robot orders exceeding 300 units and global installations surpassing 200. However, the current price of 20.02 HKD is 43.35% below the 52-week high of 35.34 HKD, below the 20-day MA of 23.34 HKD and 60-day MA of 25.20 HKD, with YTD decline of 18.09%, as the market remains cautious about earnings sustainability.